

(51) International Patent Classification:
C07D 413/04 (2006.01)(21) International Application Number:
PCT/US2015/052474(22) International Filing Date:
25 September 2015 (25.09.2015)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/055,604 25 September 2014 (25.09.2014) US(71) Applicant: UNIVERSITY OF NOTRE DAME DU LAC
[US/US]; Office Of Technology Transfer, 940 Grace Hall,
Notre Dame, Indiana 46556 (US).(72) Inventors: **CHANG, Mayland**; 14542 Heatherton Drive,
Granger, Indiana 46530 (US). **MOBASHERY, Shahriar**;
14542 Heatherton Drive, Granger, Indiana 46530 (US).
SPINK, Edward; 20 Shrigley Road, Bolington Cheshire
SK10 5QU (GB). **DING, Derong**; 3427 Newburg Court,
#D, Mishawaka, Indiana 46545 (US). **TESTERO, Se-**
bastian; Italia 2971 2do piso depto 1, Rosario, Santa Fe(AR). **LEEMANS, Erika**; F. De Pillecijnlaan 14, B-9220
Hamme (BE). **BOUDREAU, Marc A.**; W223 Parsons
Hall, 23 Academic Way, Durham, New Hampshire 03824-
3598 (US).(74) Agent: **HAUKAAS, Michael H.**; Haukaas Fortius PLLC,
5100 Eden Ave., Suite 303, Edina, Minnesota 55436 (US).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,

[Continued on next page]

(54) Title: NON-BETA LACTAM ANTIBIOTICS




Figure 1

(57) Abstract: The invention provides a newly
discovered oxadiazole class of antibiotics. The ox-
adiazoles impair cell-wall biosynthesis and exhibit
activities against the Gram-positive bacteria such
as the bacterium *Staphylococcus aureus*, including
methicillin-resistant *S. aureus* (MRSA) and van-
comycin-resistant and linezolid-resistant *S. aureus*.
For example, 5-(1H-indol-5-yl)-3-(4-(4-(tri-
fluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole
(antibiotic 75b) was efficacious in a mouse model
of MRSA infection, exhibiting a long half-life, a
high volume of distribution, and low clearance.
Antibiotic 75b antibiotic is bactericidal and is or-
ally bioavailable. This class of antibiotics can be
used as a therapeutic agent against infections by
Gram-positive bacteria such as MRSA.



DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

26 May 2016